Lion Point Capital’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-39,589
| Closed | -$153K | – | 24 |
|
|
2024
Q3 | $153K | Sell |
39,589
-51,205
| -56% | -$142K | 0.34% | 22 |
|
|
2024
Q2 | $211K | Hold |
90,794
| – | – | 0.38% | 22 |
|
|
2024
Q1 | $256K | Hold |
90,794
| – | – | 0.14% | 26 |
|
|
2023
Q4 | $289K | Hold |
90,794
| – | – | 0.14% | 24 |
|
|
2023
Q3 | $300K | Buy |
90,794
+12,443
| +16% | +$38.8K | 0.13% | 27 |
|
|
2023
Q2 | $259K | Buy |
78,351
+27,146
| +53% | +$95.8K | 0.12% | 27 |
|
|
2023
Q1 | $169K | Hold |
51,205
| – | – | 0.07% | 26 |
|
|
2022
Q4 | $732K | Hold |
51,205
| – | – | 0.1% | 27 |
|
|
2022
Q3 | $732K | Hold |
51,205
| – | – | 0.16% | 34 |
|
|
2022
Q2 | $732K | Hold |
51,205
| – | – | 0.08% | 38 |
|
|
2022
Q1 | $481K | Hold |
51,205
| – | – | 0.11% | 32 |
|
|
2021
Q4 | $354K | Sell |
51,205
-355,987
| -87% | -$2.99M | 0.09% | 30 |
|
|
2021
Q3 | $3.87M | Hold |
407,192
| – | – | 0.73% | 23 |
|
|
2021
Q2 | $4.07M | Hold |
407,192
| – | – | 0.7% | 24 |
|
|
2021
Q1 | $4.76M | Hold |
407,192
| – | – | 0.87% | 20 |
|
|
2020
Q4 | $14.5M | Hold |
407,192
| – | – | 2.8% | 12 |
|
|
2020
Q3 | $5.63M | Hold |
407,192
| – | – | 1.23% | 16 |
|
|
2020
Q2 | $6.71M | Hold |
407,192
| – | – | 1.63% | 16 |
|
|
2020
Q1 | $3.46M | Buy |
407,192
+61,111
| +18% | +$854K | 0.91% | 19 |
|
|
2019
Q4 | $7.88M | Buy |
+346,081
| New | +$4.94M | 0.73% | 19 |
|
Lion Point Capital's LUMO Position: Q4 2024 in Review
Lion Point Capital sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 39,589 shares — an estimated $153K sold.
Lion Point Capital first reported a position in LUMO in Q4 2019 and held it in 20 quarters. The position peaked at $14.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Lion Point Capital reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Lion Point Capital sold 39,589 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $153K.
- Lion Point Capital first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2019 and held it in 20 quarters.
- Lion Point Capital's Lumos Pharma, Inc. Common Stock position peaked at $14.5M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Lion Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.